Form 4: Apellis Pharmaceuticals Executive Exercises Stock Options

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options to acquire 24,500 shares of common stock.

Summary

• On May 20, 2024, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options.
• This transaction resulted in the acquisition of 24,500 shares of Apellis Pharmaceuticals common stock at a price of $3.76 per share.
• Following the transaction, Deschatelets directly owns 1,140,483 shares of common stock and 12,780 derivative securities.
• The stock option exercised was granted on February 8, 2016, and was fully vested.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard insider transaction. It doesn't inherently indicate positive or negative news about the company's performance.

Positives

• The exercise of stock options by a high-ranking executive could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, primarily providing transparency to shareholders regarding executive compensation and stock ownership.

Key Dates